TY - JOUR
T1 - Stem cells, organoids, and organ-on-a-chip models for personalized in vitro drug testing
AU - van Berlo, Damiën
AU - Nguyen, Vivian V.T.
AU - Gkouzioti, Vasiliki
AU - Leineweber, Kirsten
AU - Verhaar, Marianne C.
AU - van Balkom, Bas W.M.
N1 - Funding Information:
The authors would like to thank the sponsors of our research: Health∼Holland TKI-LSH grant ‘REDUCE MORE! ’, grant number LSHM18045 (to B.W.M. v.B.), the Dutch Heart Foundation CVON2014-11 ‘RECONNECT’ and ‘RECONNEXT’ (to M.C.V.), and RECONNECT YTP ‘CHIPS’ (to B.W.M.v.B.) grants; the EU H2020 research and innovation program under Marie S. Curie Cofund RESCUE grant agreement No 801540 (to M.C.V.). The authors are also financially supported by the Gravitation Program ‘Materials Driven Regeneration,’ funded by the Netherlands Organization for Scientific Research (024.003.013) (to M.C.V.), the Dutch Kidney Foundation (PIONIER+ grant 19OP+007), the Dutch Society for the Replacement of Animal Testing, ZonMW/SGF, and TKI/Health∼Holland ( BIQMIMETICS; research programme Human Measurement Models , grant numbers 114025102 and LSHM20046-SGF ).
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/12
Y1 - 2021/12
N2 - Breakthroughs in stem cell biology and microfluidics technology have opened doors to in vitro screening platforms for personalized testing of safety (pharmaceuticals, nutrients, chemicals) and efficacy (pharmaceuticals, nutraceuticals). Major breakthrough technologies include development of induced pluripotent stem cells, the development of induced pluripotent stem cell-derived organoids and adult stem cell-derived organoids, and the generation of organ-on-a-chip and multi-organ-on-a-chip models to mimic human physiology in vitro. These technologies are highly complementary and offer tremendous potential for improved efficiency in drug development and chemical safety testing. In the current review, we will provide an overview of recent advances in in vitro modeling for personalized drug testing based on stem cell and organ-on-a-chip technologies and illustrate how these developments will eventually lead to the replacement of animal testing. Particular focus will be on multi-organ-on-chip human disease models, which have the potential to be the gold standard of the future for the investigation of safety, toxicity, and efficacy of newly developed medicines.
AB - Breakthroughs in stem cell biology and microfluidics technology have opened doors to in vitro screening platforms for personalized testing of safety (pharmaceuticals, nutrients, chemicals) and efficacy (pharmaceuticals, nutraceuticals). Major breakthrough technologies include development of induced pluripotent stem cells, the development of induced pluripotent stem cell-derived organoids and adult stem cell-derived organoids, and the generation of organ-on-a-chip and multi-organ-on-a-chip models to mimic human physiology in vitro. These technologies are highly complementary and offer tremendous potential for improved efficiency in drug development and chemical safety testing. In the current review, we will provide an overview of recent advances in in vitro modeling for personalized drug testing based on stem cell and organ-on-a-chip technologies and illustrate how these developments will eventually lead to the replacement of animal testing. Particular focus will be on multi-organ-on-chip human disease models, which have the potential to be the gold standard of the future for the investigation of safety, toxicity, and efficacy of newly developed medicines.
KW - Advanced in vitro models
KW - Animal free innovations
KW - Drug efficacy
KW - Drug safety
KW - Personalized Medicine
UR - http://www.scopus.com/inward/record.url?scp=85122702587&partnerID=8YFLogxK
U2 - 10.1016/j.cotox.2021.08.006
DO - 10.1016/j.cotox.2021.08.006
M3 - Review article
AN - SCOPUS:85122702587
VL - 28
SP - 7
EP - 14
JO - Current Opinion in Toxicology
JF - Current Opinion in Toxicology
ER -